Transplant Patients' Perceptions About Participating in First-in-Human Pig Kidney Xenotransplant Clinical Trials: A Mixed Methods Study

被引:0
|
作者
Gordon, Elisa J. [1 ,2 ]
Maschke, Karen J. [3 ]
Gacki-Smith, Jessica [4 ]
Brooks, Hannah L. [5 ]
Matthews, Margaret M. [6 ]
Traboulsi, Karen [7 ]
Manning, Dahlya [8 ]
Leventhal, Joseph [9 ]
Gusmano, Michael K. [10 ]
机构
[1] Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Ctr Biomed Ethics & Soc, Med Ctr, Nashville, TN 37232 USA
[3] Hastings Ctr, Garrison, NY USA
[4] Northwestern Univ, Feinberg Sch Med, Ctr Hlth Serv & Outcomes Res, Chicago, IL USA
[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[6] Harvard TH Chan Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA USA
[7] Lehigh Univ, Dept Ind & Syst Engn, Bethlehem, PA USA
[8] Northwestern Univ, Comprehens Transplant Ctr, Feinberg Sch Med, Chicago, IL USA
[9] Northwestern Univ, Feinberg Sch Med, Dept Surg, Div Transplantat, Chicago, IL USA
[10] Lehight Univ, Coll Hlth, Dept Populat Hlth, Bethlehem, PA USA
关键词
attitudes; decision-making; efficacy; ethics; informed consent; patient-centered; qualitative; recruitment; safety; survey; DESIGN; TRUST;
D O I
10.1111/xen.70013
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
First-in-human pig xenotransplant clinical trials may soon begin, which raises ethical concerns about patients' decision-making to participate in such trials. We assessed kidney transplant candidates' attitudes and hypothetical decision-making about participating in xenotransplant trials through semi-structured telephone interviews and an online survey. We analyzed qualitative data by thematic analysis and quantitative data by descriptive statistics. Twenty-eight patients participated in interviews; 142 patients participated in the survey. Most interview and survey respondents were male (68%, 56%), White (54%, 61%), or Black (36%, 22%). Although interview participants appreciated xenotransplantation research's potential to advance science, they expressed concerns about infection transmission and graft function. Few survey respondents were willing to participate in a pig kidney trial to test the safety of pig kidneys (12.6%) or pig kidney function (16.9%). Interview participants would be more likely to participate in a first-in-human pig kidney trial if receiving a human kidney was unlikely and their health status declined. Willingness would also depend on how long the pig kidney would function. Most interview participants were receptive to long-term monitoring, but not to family monitoring. Transplant programs planning xenotransplant trials should anticipate these types of concerns for optimizing human subject protections and conducting a robust informed consent process.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] AN INTEGRATED FIRST-IN-HUMAN STUDY DESIGN INVOLVING SEQUENTIAL SINGLE AND MULTIPLE ASCENDING DOSE COHORTS: AN EMERGING TREND IN PHASE I CLINICAL TRIALS
    Francis, M.
    Basque, J.
    Legault, E.
    Rufiange, M.
    Sicard, E.
    Lefebvre, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S20 - S21
  • [32] A mixed-methods study of healthcare provider perspectives on the barriers to enrollment of minority patients on cancer clinical trials.
    Kim, Yonghun
    O'Shea, Mary
    Asiedu, Gladys
    Price, Katharine Andress Rowe
    Warsame, Rahma M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18544 - E18544
  • [33] A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma
    Kumthekar, Priya
    Ko, Caroline H.
    Paunesku, Tatjana
    Dixit, Karan
    Sonabend, Adam M.
    Bloch, Orin
    Tate, Matthew
    Schwartz, Margaret
    Zuckerman, Laura
    Lezon, Ray
    Lukas, Rimas, V
    Jovanovic, Borko
    McCortney, Kathleen
    Colman, Howard
    Chen, Si
    Lai, Barry
    Antipova, Olga
    Deng, Junjing
    Li, Luxi
    Tommasini-Ghelfi, Serena
    Hurley, Lisa A.
    Unruh, Dusten
    Sharma, Nitya, V
    Kandpal, Manoj
    Kouri, Fotini M.
    Davuluri, Ramana, V
    Brat, Daniel J.
    Muzzio, Miguel
    Glass, Mitchell
    Vijayakumar, Vinod
    Heidel, Jeremy
    Giles, Francis J.
    Adams, Ann K.
    James, C. David
    Woloschak, Gayle E.
    Horbinski, Craig
    Stegh, Alexander H.
    SCIENCE TRANSLATIONAL MEDICINE, 2021, 13 (584)
  • [34] Telehealth-Delivered Program and Accompanying Patients to Enhance the Clinical Condition of Patients Throughout a Liver Transplant: Protocol for a Mixed Methods Study
    Pomey, Marie -Pascale
    Le Roux, Enora
    Nadon, Nathalie
    Perron, Jessie
    Barry, Angele
    Bemeur, Chantal
    Poder, Thomas G.
    Duford, Fernand
    Laviolette, Louise
    Tetrault-Lassonde, Johanne
    Vialaron, Cecile
    Escalona, Manuel J.
    Normandin, Louise
    Huard, Genevieve
    Girardin, Catherine
    Rose, Christopher
    Malas, Kathy
    Ouellet, Denis
    Vincent, Catherine
    JMIR RESEARCH PROTOCOLS, 2024, 13
  • [35] A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors
    Vernet, Remi
    Fernandez, Eugenio
    Migliorini, Denis
    Ancrenaz, Virginie
    Charrier, Emily
    Belkouch, Marie-Claude
    Von Rohr, Olivier
    Urwyler, Muriel
    De Vito, Claudio
    Renaux, Jessica
    Villard, Jean
    Rubin, Olivier
    Grogg, Julien
    Mach, Nicolas
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (08): : 2089 - 2100
  • [36] Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors
    Tsimberidou, Apostolia Maria
    Rudek, Michelle A.
    Hong, David
    Ng, Chaan S.
    Blair, Jessica
    Goldsweig, Howard
    Kurzrock, Razelle
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (02) : 235 - 241
  • [37] Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors
    Apostolia Maria Tsimberidou
    Michelle A. Rudek
    David Hong
    Chaan S. Ng
    Jessica Blair
    Howard Goldsweig
    Razelle Kurzrock
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 235 - 241
  • [38] CLINICAL RESEARCH PROFESSIONALS' (CRPS) PERCEPTIONS OF USING ELECTRONIC PATIENT-REPORTED OUTCOME ( EPRO) DATA COLLECTION SYSTEMS IN ONCOLOGY CLINICAL TRIALS: A MIXED-METHODS STUDY
    Cho, Youmin
    Jiang, Yun
    Saint Arnault, Denise
    Williams, David A.
    Zahrieh, David
    Zahrieh, David
    Smith, Ellen Lavoie
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [39] Regenerative therapy by fusion of medicine and engineering: First-in-human clinical trials with induced pluripotent stem cells and cell sheet technology: A report of the Symposium of Regenerative Medicine for Patients
    Okano, Teruo
    Sawa, Yoshiki
    Barber, Emma
    Umezawa, Akihiro
    REGENERATIVE THERAPY, 2015, 2 : 2 - 5
  • [40] Exploring patients' and carers' views about the clinical use of ketamine to inform policy and practical decisions: mixed-methods study
    Jilka, Sagar
    Murray, Claire
    Wieczorek, Ania
    Griffiths, Helena
    Wykes, Til
    McShane, Rupert
    BJPSYCH OPEN, 2019, 5 (04):